Reviewer's report

Title: Sunitinib-induced severe toxicities in Japanese patient with the ABCG2 421 AA genotype

Version: 2 
Date: 14 October 2014

Reviewer: Shiva Keshava Gaddam B

Reviewer's report:

Comments

In the case study titled Sunitibib-induced severe toxicities in Japanese patient with the ABCG2 421 AA genotype “ authors enumerate the side effects of Sunitinib administration and implicate the low bioavailability of the drug in Asian populations may be due to single nucleotide polymorphism (SNP) in ABCG2 gene following their study in this case along with the previously reported studies. This case study may be accepted for publication with some minor revisions.

1. The authors should add the word “gene/s” when mentioning the gene name (example line 171-172: single-nucleotide polymorphisms (SNPs) in CYP3A5, ABCB1 and ABCG2 genes.)

2. The authors should give the complete gene name when they are mentioning it for the first time for the convenience of the readers.

3. Please mention the method by which the authors isolated DNA from formalin fixed paraffin embedded tissue samples. If they used a kit, please mention the source.

4. Line 201- line 205: Please reframe the sentence. The result in Phase I dose escalation.......plasma concentration # 100ng/ml.

5. Line 213- 214: “that causes sunitinib higher exposure” does the authors mean high concentration of plasma levels of sunitinib? If yes please reframe the sentence.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician

Declaration of competing interests:

I declare that I have no competing interests